Archerfish & C2N Launch Breakthrough Alzheimer's Blood Test in Singapore

Archerfish Precision Diagnostics (Archerfish), a top-of-the-line diagnostic laboratory in Singapore, has collaborated with U.S.-based firm C2N Diagnostics, LLC (C2N) to bring and make available the revolutionary PrecivityAD2 blood test for Alzheimer's Disease (AD) in Singapore and other major Asian markets. The partnership represents a significant breakthrough in enhancing early and precise diagnosis of AD, fulfilling an important healthcare requirement in the region.

The alliance uses Archerfish's regional laboratory presence and patient outreach network to enable wide availability of the PrecivityAD2 test,  the first of its kind in Singapore. The test provides a non-invasive, affordable alternative to conventional AD diagnostic approaches, detecting brain amyloid pathology through a simple blood draw.

Key Highlights:

• Archerfish partners with U.S.-based C2N to launch Singapore’s first blood-based Alzheimer’s test, PrecivityAD2
• PrecivityAD2 uses high-resolution liquid chromatography and mass spectrometry to detect amyloid pathology via a simple blood draw
• The test offers non-invasive, early, and accurate diagnosis for individuals aged 55 plus, supporting timely intervention amid Singapore’s ageing population

Designed for individuals 55 years and older with cognitive issues, the test employs liquid chromatography and tandem mass spectrometry with high resolution to identify amyloid beta and tau peptides implicated in AD.

Also Read: How AI Is Enabling A Fastpaced Healthcare Sector - What To Expect In The Coming Years

"Reliable and available diagnosis is a vital pillar in the treatment of Alzheimer's Disease. With the breakthroughs in blood-based biomarkers, we are witnessing new potentialities that complement conventional diagnostic approaches and facilitate earlier clinical decision-making. These advances hold out the prospect of enhancing care for people who are suffering from cognitive decline," stated Professor Christopher Chen, Director, Memory Aging and Cognition Centre, National University Health System.

As Singapore's ageing population is projected to increase cases of dementia, PrecivityAD2 provides higher diagnostic confidence, allowing early intervention or excluding AD to prevent unwarranted procedures. This alliance equips clinicians and patients with quicker, accurate tools to enhance outcomes and reduce treatment pathways for cognitive disorders.